Assessing blood carboxyhemoglobin levels as an early predictor of phototherapy in ABO incompatible newborns

Abstract

Background

This study aimed to evaluate blood carboxyhemoglobin (COHb) levels as an indicator of hemolysis and as an early predictor of phototherapy requirement in newborns with blood type A or B born to mothers with blood type O.

Methods

In this prospective observational study, enrolled infants were divided into two groups: Group 1 comprised newborns with maternal blood type O and infant blood type A or B, while Group 2 consisted of newborns born to mothers without blood type O. Total serum bilirubin and carboxyhemoglobin levels were assessed from cord blood samples at birth and venous blood samples at 24 h of life and compared between groups. None of the infants required intravenous immunoglobulin therapy or blood transfusion.

Results

A total of 100 term infants were included. Mean carboxyhemoglobin levels in cord blood and at 24 h of life were significantly higher in Group 1 compared with Group 2 (0.55 vs 0.48, p = 0.04; 0.69 vs 0.36, p = 0.002, respectively). The onset of phototherapy occurred significantly earlier in Group 1 than in Group 2 (48 vs 90 h, p = 0.01).

Conclusion

Elevated carboxyhemoglobin levels were observed in newborns with ABO incompatibility, and higher levels were associated with an earlier requirement for phototherapy.

Keywords

ABO incompatibility carboxyhemoglobin hyperbilirubinemia newborn phototherapy

Get full access to this article

View all access options for this article.

References

Anderson

Calkins

. Neonatal indirect hyperbilirubinemia. NeoReviews 2020; 21: e749–e760.

Aktas

Dogan

Okmen

, et al.

Is cord blood bilirubin level a reliable predictor for developing significant hyperbilirubinemia?

Am J Perinatol 2019; 36: 317–321.

Lauer

Spector

. Hyperbilirubinemia in the newborn. Pediatr Rev 2011; 32: 341–349.

Olusanya

Kaplan

Hansen

TWR

. Neonatal hyperbilirubinaemia: a global perspective, Lancet Child Adolesc Health 2018; 2: 610–620.

Sarici

Yurdakok

Serdar

, et al. An early (sixth-hour) serum bilirubin measurement is useful in predicting the development of significant hyperbilirubinemia and severe ABO hemolytic disease in a selective high-risk population of newborns with ABO incompatibility. Pediatrics 2002; 109: e53.

Shen

, et al. Neonatal hyperbilirubinemia management: clinical assessment of bilirubin production, Semin Perinatol 2021; 45: 151351.

Roberts

IAG

. The changing face of haemolytic disease of the newborn. Early Hum Dev 2008; 84: 515–523.

Matteocci

De Rosa

Buffone

, et al. Retrospective analysis of HDFN due to ABO incompatibility in a single institution over 6 years. Transfus Med 2019; 29: 197–201.

Coban

Kaynak Turkmen

Gursoy

. Turkish neonatal society guideline to the approach, follow-up, and treatment of neonatal jaundice. Turk Pediatri Ars 2018; 53: S172–S179.

10.

Mehta

Petrova

. Direct antiglobulin test in the prediction of hyperbilirubinemia and predischarge bilirubin levels in infants with mother-infant blood type incompatibility. Pediatr Neonatol 2021; 62: 406–411.

11.

Zantek

Koepsell

Tharp

JDR

, et al. The direct antiglobulin test: a critical step in the evaluation of hemolysis. Am J Hematol 2012; 87: 707–709.

12.

Lozar-Krivec

Bratanic

Paro-Panjan

. The role of carboxyhemoglobin measured with CO-oximetry in the detection of hemolysis in newborns with ABO alloimmunization. J Matern Fetal Neonatal Med 2016; 29: 452–456.

13.

Lozar-Krivec

Manfreda

Paro-Panjan

. Clinical factors influencing endogenous carbon monoxide production and carboxyhemoglobin levels in neonates. J Pediatr Hematol Oncol 2022; 44: e84–e90.

14.

Herschel

Karrison

Wen

, et al. Evaluation of the direct antiglobulin (coombs’) test for identifying newborns at risk for hemolysis as determined by end-tidal carbon monoxide concentration (ETCOc); and comparison of the coombs’ test with ETCOc for detecting significant jaundice. J Perinatol 2002; 22: 341–347.

15.

Christensen

Bahr

Wong

, et al. A “Gold Standard” test for diagnosing and quantifying hemolysis in neonates and infants. J Perinatol 2023; 43(12): 1541–1547. doi:10.1038/s41372-023-01730-4.

16.

Javier

Krauss

Nesin

. Corrected end-tidal carbon monoxide closely correlates with the corrected reticulocyte count in coombs’ test-positive term neonates. Pediatrics 2003; 112: 1333–1337.

17.

American Academy of Pediatrics . Clinical practice guideline, subcommittee on hyperbilirubinemia. Management of the newborn 35 or more weeks of gestation. Pediatrics 2004; 114: 297–316.

18.

Guney

Mengi

Dogan

, et al. Elevated blood carboxyhemoglobin levels as an early predictor of phototherapy requirement in moderate and late preterm infants. J Matern Fetal Neonatal Med 2020; 33: 1441–1446.

19.

Schutzman

Gatien

Ajayi

, et al. Carboxyhemoglobin levels as a predictor of risk for significant hyperbilirubinemia in African-American DAT+ infants. J Perinatol 2016; 36: 386–388.

20.

Ozolek

Watchko

Mimouni

. Prevalence and lack of clinical significance of blood group incompatibility in mothers with blood type A or B. J Pediatr 1994; 125: 87–91.

21.

Christensen

Baer

MacQueen

, et al. ABO hemolytic disease of the fetus and newborn: thirteen years of data after implementing a universal bilirubin screening and management program. J Perinatol 2018; 38: 517–525.